TherapeuticsMD, Inc. (TXMD) 2025 Annual Report: Key Investor Insights

Executive Summary

TherapeuticsMD, Inc. released its 2025 Annual Report, detailing its transition to a pharmaceutical royalty company, financial challenges, ongoing disputes, and risks that may significantly impact shareholder value. The company is now focused on receiving royalties from licensed women’s healthcare products, following the divestiture of direct commercial operations.

Key Highlights

• Transition to Royalty Model: After the December 2022 transaction with Mayne Pharma, TherapeuticsMD now derives all revenues from royalties on women’s healthcare products licensed to other pharmaceutical companies. This shift means the company’s fortunes are closely tied to the performance of its licensees.
• Products Under License: Current royalty-generating products include IMVEXXY, BIJUVA, ANNOVERA, BocaGreenMD and vitaMedMD brands. Mayne Pharma holds exclusive commercialization rights for these products in relevant territories.
• Financial Position and Liquidity: The company faces significant liquidity concerns, including the risk of not being able to continue as a going concern for the next twelve months. If royalty revenues decline, or if disputes with Mayne Pharma result in unfavorable outcomes, the company may need to raise additional capital, potentially diluting existing shareholders.
• Disputes with Mayne Pharma: There are ongoing disagreements regarding payer rebates, wholesale distributor fees, and working capital settlements. Mayne Pharma’s calculations differ materially from TherapeuticsMD’s estimates, which could affect cash flows and the company’s financial position.
• Nasdaq Listing Risks: Following the business transition, TXMD may be considered a “public shell” company under Nasdaq rules, which could lead to delisting proceedings. Loss of Nasdaq listing would severely impact liquidity, market price, and investor access.
• Major Shareholder Control: Rubric Capital Management LP and affiliates own approximately 25.5% of TXMD’s common stock, giving them significant influence over corporate decisions, including director elections and major transactions.
• Net Operating Loss Carryforwards: As of December 31, 2025, TXMD has federal NOLs of \$584.6 million, which may be used to offset future taxable income, subject to limitations.
• Management Turnover: The company has experienced significant turnover in senior management, including termination of top executives post-Mayne transaction, with new leadership appointed from within.
• Risk Factors: The report details numerous risks, including reliance on licensee sales, inability to raise capital, disputes affecting revenue, potential Nasdaq delisting, significant turnover in management, subleasing liabilities, and risks related to intellectual property and product liability.

Potentially Price Sensitive Issues for Shareholders

• Liquidity and Going Concern: The company warns of substantial doubt about its ability to continue as a going concern. If additional capital is not raised, operations may be curtailed or discontinued, or assets may be sold at unfavorable prices. This is a critical risk for shareholders.
• Ongoing Disputes with Mayne Pharma: Disagreements over working capital and rebates may materially affect cash flows and financial results. Unfavorable outcomes could force further capital raising or asset sales.
• Nasdaq Delisting Risk: TXMD may be classified as a public shell, risking delisting from Nasdaq. Delisting would reduce liquidity, depress share price, and restrict investor access. The company has no current plans to delist, but the risk remains.
• Dilution Risk: If new equity or debt is raised, existing shareholders may face dilution. The terms of any new securities may include preferences that adversely affect current shareholders.
• Control by Major Shareholder: Rubric Capital’s large stake means shareholder votes and major corporate actions may be dominated by a single investor group.
• No Dividend Policy: The company does not anticipate paying dividends for the foreseeable future. Returns will be limited to capital appreciation, if any.
• Intellectual Property and Product Liability: Risks include disputes over licensing agreements, potential litigation, and the need to defend or indemnify licensees, which could be costly and affect operations.
• Volatility and Market Risks: The report notes that share price may be highly volatile, subject to changes in product sales, legal outcomes, management turnover, and market perception.

Detailed Analysis

Financials and Capital Raising

TXMD’s cash position is precarious. If royalty revenues do not increase or if disputes with Mayne Pharma are resolved unfavorably, the company may seek capital through private placements or public offerings. Any such actions will dilute existing shareholders and may introduce terms unfavorable to them. Failure to secure financing could lead to drastic restructuring or even cessation of operations.

Royalty Business Model Risks

TXMD’s revenues are entirely dependent on the success of its licensees. Any reduction in sales, coverage, or reimbursement for IMVEXXY, BIJUVA, ANNOVERA, or related products may materially impact revenues. The company has no direct control over marketing or sales, increasing risk.

Legal and Contractual Disputes

Disputes with Mayne Pharma over rebates, fees, and working capital settlements are ongoing. Calculations provided by Mayne differ significantly from TXMD’s estimates, and resolution may affect both cash flow and reported earnings. Litigation or arbitration may be necessary, with uncertain outcomes.

Nasdaq Listing and Public Shell Status

After transitioning to a royalty company, TXMD may be deemed a public shell under Nasdaq rules. This status could trigger delisting proceedings, resulting in loss of liquidity, reduced share price, and inability to use certain SEC exemptions (Rule 144, Form S-8). Delisted shares would trade OTC, subject to lower regulatory standards.

Major Shareholder Influence

Rubric Capital Management LP and affiliates can exert significant control, potentially overriding minority shareholder interests. This may affect director elections, mergers, and other major decisions.

Management Turnover

Significant changes in senior management could disrupt operations, hinder strategy execution, and increase uncertainty.

Net Operating Losses

TXMD has substantial NOLs that could offset future taxable income, but utilization depends on generating profits and is subject to regulatory limitations.

Risk Summary

Principal risks include dependence on licensee sales, liquidity issues, ongoing disputes, Nasdaq delisting, shareholder dilution, management turnover, legal liabilities, and volatility. Any of these could materially impact share value.

Conclusion

TherapeuticsMD’s 2025 Annual Report reveals a company in transition, facing significant financial, operational, and regulatory risks. Shareholders should be aware of the liquidity challenges, ongoing disputes, Nasdaq listing risks, and potential dilution. These issues may significantly impact share value and should be monitored closely.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with financial advisors before making investment decisions. The information herein is based on the company’s annual report and may contain forward-looking statements subject to risks and uncertainties.

View TherapeuticsMD, Inc. Historical chart here